The US Food and Drug Administration rejects Capricor Therapeutics’ Duchenne muscular dystrophy cell therapy, deramiocel. BioPharma Dive reports the FDA issued an unusual statement accusing Capricor of “serious data integrity violations” that compromised the study findings, leading to deramiocel’s second rejection since 2025.
STAT News also reports the FDA denial of the therapy for patients with Duchenne muscular dystrophy and describes the decision as long anticipated. While both outlets focus on the FDA’s rejection, BioPharma Dive emphasizes the regulator’s specific concern about data integrity and the fact that it is the second rejection in the recent period. STAT’s coverage is more centered on the timing and the overall decision rather than detailing the underlying compliance allegation.
Across both reports, the central point is that the FDA does not approve the Duchenne therapy application presented by Capricor, and the stated reason highlighted by one outlet is related to integrity of the submitted data supporting the clinical findings.